Biogen Inc [BIIB] stock is trading at $177.08, up 0.43%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BIIB shares have gain 4.22% over the last week, with a monthly amount drifted -2.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on December 10, 2025, when HSBC Securities downgraded its rating to a Reduce but kept the price target unchanged to $143 for it. Previously, Stifel upgraded its rating to Buy on November 06, 2025, and kept the price target unchanged to $202. On September 25, 2025, Jefferies initiated with a Buy rating and assigned a price target of $190 on the stock. HSBC Securities downgraded its rating to a Hold but $118 remained the price target by the analyst firm on April 28, 2025. Argus downgraded its rating to Hold for this stock on April 04, 2025. In a note dated February 11, 2025, Bernstein initiated an Mkt Perform rating and provided a target price of $160 on this stock.
Biogen Inc [BIIB] stock has fluctuated between $110.04 and $185.17 over the past year. Currently, Wall Street analysts expect the stock to reach $172.86 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $177.08 at the most recent close of the market. An investor can expect a potential drop of -2.38% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Biogen Inc [NASDAQ:BIIB] reported sales of 9.69B for the trailing twelve months, which represents a growth of 3.33%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 175.66 points at the first support level, and at 174.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 177.85, and for the 2nd resistance point, it is at 178.61.
Ratios To Look Out For
For context, Biogen Inc’s Current Ratio is 2.72. As well, the Quick Ratio is 2.04, while the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 2.68, the price to book ratio is 1.43 and price to earnings (TTM) ratio is 16.15.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Sep 02 ’25 when 517.0 shares were sold. Officer, Singhal Priya completed a deal on Sep 02 ’25 to buy 517.0 shares. Meanwhile, Head of Global Product Strat. Izzar Rachid sold 2223.0 shares on Jul 08 ’25.
